Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
Trishula Therapeutics, Inc.
Actuate Therapeutics Inc.
Eastern Cooperative Oncology Group
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
University of California, San Francisco